Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China flag China · Delayed Price · Currency is CNY
19.89
-0.79 (-3.82%)
Nov 17, 2026, 3:00 PM CST

Nanjing Vazyme Biotech Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
0.99-16.61-18.09-70.96594.25678.29
Depreciation & Amortization
134.67134.67152.51157.38122.155.28
Other Amortization
69.5269.5260.8178.2694.8327.92
Loss (Gain) From Sale of Assets
0.290.292.1-5.670.22-0.01
Asset Writedown & Restructuring Costs
0.420.421.81.73236.852.35
Loss (Gain) From Sale of Investments
-57.73-57.73-59.9-50.92-88.02-29.81
Provision & Write-off of Bad Debts
18.7918.7920.26-7.2791.6812.08
Other Operating Activities
72.7451.4457.34165.4333.0746.61
Change in Accounts Receivable
22.7822.78-188.25534.67-682.89-133.2
Change in Inventory
-19.55-19.55-39.04-124.37-403.82-148.94
Change in Accounts Payable
59.8259.82-13-511.13464.58113.78
Change in Other Net Operating Assets
-9.88-9.8853.5625.287.377.47
Operating Cash Flow
272.06233.16-9.68152.99735.17616.8
Operating Cash Flow Growth
75.68%---79.19%19.19%-23.24%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-29.98-47.39-74.9-232.9-962.86-261.96
Sale of Property, Plant & Equipment
3.163.172.4713.4815.592.73
Cash Acquisitions
-----117.93-
Investment in Securities
-6.05-339.38395.03-726.6551.07-1,195
Other Investing Activities
60.6463.5752.645.4261.726.15
Investing Cash Flow
27.78-320.03375.21-900.65-952.44-1,428

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-919.391,1051,461372-
Long-Term Debt Issued
-9.630.020.56--
Total Debt Issued
1,658929.021,1051,462372-
Short-Term Debt Repaid
--941.36-1,723-638.79-156.41-39.56
Total Debt Repaid
-1,745-941.36-1,723-638.79-156.41-39.56
Net Debt Issued (Repaid)
-87.87-12.34-618.8822.77215.59-39.56
Issuance of Common Stock
30.67138.5--2,129
Repurchase of Common Stock
-4.62-4.62-104.4-20.01--
Common Dividends Paid
-213.23-77.46-80.36-533.33-132.24-4.45
Other Financing Activities
-35.78-48.62-21.21-19.63-4.3-15.2
Financing Cash Flow
-310.84-142.05-786.27249.879.052,070

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-3.282.94-4.241.465.04-2.32
Net Cash Flow
-14.28-225.98-424.98-496.4-133.181,256

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
242.09185.77-84.58-79.91-227.69354.84
Free Cash Flow Growth
112.09%-----45.49%
Free Cash Flow Margin
15.55%13.48%-6.14%-6.21%-6.38%18.99%
Free Cash Flow Per Share
0.370.34-0.18-0.16-0.440.75
Levered Free Cash Flow
269.41160.3-119.87-102.16-451.34181.59
Unlevered Free Cash Flow
282.96175.4-102.83-80.25-443.54184

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
13243.5945.5599.76146.72175.67
Change in Working Capital
32.3632.36-226.5-114.95-649.81-175.9